MAO-B inhibitors
Selegiline, rasagiline and safinamide — symptomatic effect, off-time reduction and any disease-modification signal.
State of the art
No update yet for MAO-B inhibitors. An update is a standalone state-of-the-art for the topic — what someone with Parkinson's needs to know about where this approach stands today.
No reader summaries on this topic yet.